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Aim. At present, little data exist about incidence and the risk factors associated with metabolic syndrome (MetS) in patients with
type 2 diabetes mellitus (T2DM). The objectives of present study were to assess the incidence and risk factors of MetS in people
with T2DM. Methods. During the mean (SD) follow-up period of 11.7 (4.8) years, 3,047 patients with T2DM and free of MetS at
baseline have been examined to determine incidence and predictors of progression to MetS. A modiﬁed the National Cholesterol
Education Program—Adult Treatment Panel III deﬁnition with body mass index (BMI) instead of waist circumference was used
for the MetS. Results. The prevalence of MetS was 63.2% (95% CI: 62.3, 64.1). The incidence of MetS was 28.5 (95% CI: 26.8, 30.2)
(25.9 men and 30.9 women) per 1,000 patient-years based on 35,677 patient-years of follow-up. Multivariate analysis revealed that
higher BMI and education, lower HbA1c and treatment with oral agent or insulin were associated with MetS. Conclusion.T h e s e
are the ﬁrst estimate of incidence and risk factors of MetS in patients with T2DM in Iran. These ﬁndings showed that the natural
course of MetS is dynamic. The clinical management of patients with T2DM will contribute signiﬁcantly to MetS prevention.
1.Introduction
Metabolic syndrome (MetS) is an important public health
problem worldwide, and its prevalence is increasing [1, 2].
Patients with MetS are at higher risk for many long-term
complications, including micro- and macro-vascular com-
plications [2]. This is particularly relevant in patients with
type2diabetesmellitus(T2DM),whoareatevengreatercar-
diovascular risk [3]. In fact,cardiovascular complications are
the most common cause of morbidity and mortality in pa-
tients with T2DM [4]. The relationship between MetS and
diabetes and cardiovascular disease is well established and
consistent and has been examined in many diﬀerent popula-
tions [3, 5, 6]. T2DM and cardiovascular disease have many
risk factors in common, and many of these risk factors are
highly correlated with one another [5, 7]. MetS is very com-
mon among patients with T2DM, using the Third Report
of the National Cholesterol Education Program Adult Treat-
ment Panel (NCEP/ATP III) deﬁnition; over 65% of patients
with T2DM have MetS [8]. This is much higher prevalence
than in comparable general populations [9, 10]. The higher
prevalence of MetS in patients with T2DM may be explained
by medication-, disease-, and lifestyle-related factors. Lim-
ited information is available about the incidence of the MetS
and its risk factors in patients with T2DM and none in Iran.
Accurate information regarding the incidence of MetS
andassociatedriskfactorsinpeoplewithT2DMisimportant
to get a better understanding of natural course of metabolic
and cardiovascular risk in a non-preselected cohort of dia-
betic patients in routine practice.
Thisstudy,therefore,usedroutinelycollecteddatafroma
clinical information system for diabetes at Isfahan Endocrine
and Metabolism Research Center, Iran, to estimate the
incidence of MetS and to identify its risk factors in a large
sample of diabetic patients receiving routine care.
2. Patients andMethods
2.1.ParticipantsandDataCollection. Therecruitmentmeth-
ods and examination procedures of the Isfahan Endocrine2 ISRN Endocrinology
and Metabolism Research Center outpatient clinics have
been described before [11, 12]. In summary, clinical data are
collected for all consecutive patients at the ﬁrst attendance
andatreviewconsultations(usuallyannually)usingstandard
encounter forms. These include an examination of ocular
fundus and lens, the limbs, and blood pressure (BP); mea-
surement of height, weight, fasting plasma glucose (FPG),
glycosylated haemoglobin (HbA1c), urine protein, triglyc-
eride, cholesterol, and serum creatinine levels. The clinician
compiles a list of problems and smoking is reported via
a questionnaire completed by the patients on demography,
family history, and smoking.
Generally, newly diagnosed patients are referred to quali-
ﬁed nutritionists for evaluation; if necessary, a lifestyle and
weight management program is recommend. All newly dia-
gnosedpatientsattendweight-relatedhealtheducationclass-
es free of charge.
2.2. Participants. Using routinely collected data from a clini-
calinformationsystematIsfahanEndocrineandMetabolism
Research Centre, Iran, we performed a retrospective longitu-
dinal, observational study. The study population consisted of
all prevalent cases of T2DM, and all patients were diagnosed
during the study period. Between 1992 and 2009, a total of
11,281 patients with T2DM were registered in the system.
However,this study uses data only for3,047 of these patients,
that is, 1,461 (47.9%) men and 1,586 (52.1%) women who
hadatleastonesubsequentreviewsinceregistrationandwho
were free of MetS at baseline. The physician deﬁned the type
of diabetes according to the American Diabetes Association
criteria [13].
The study conformed to the Declaration of Helsinki. Ins-
titutionalethicalcommitteeapprovalwasgranted,andanin-
formed consent was signed by each patient.
2.3. Ascertainment of MetS. A minimally modiﬁed
NCEP/ATP III [14] deﬁnition with body mass index (BMI)
instead of waist circumference was used for the MetS by the
presence of three or more of the following abnormalities:
blood pressure ≥ 130/85mmHg or a history of hypertension
and current use of antihypertensive treatment; BMI ≥
25kg/m2;s e r u mt r i g l y c e r i d e≥ 150mg/dL (≥1.7mmol/L);
high-density lipoprotein cholesterol (HDL; <40mg/dL
(<0.9mmol/L) for men and < 50mg/dL (<1.0mmol/L) for
women);known diabetes mellitus.BMI ≥ 25kg/m2 wasused
instead since waist circumference was not available. In some
otherstudies,BMIhasbeenadoptedinsteadofwaistcircum-
ference for analysis of MetS [5, 8, 15, 16].
2.4. Procedures. Predictors of progression to MetS were as-
sessedusingthefollowingdatafromthepatient’sregistration
consultation: gender, age at diagnosis (i.e., at the time
this was ﬁrst recorded by a physician on the participant’s
chart), current age (at the time of examination), educational
level, duration of diabetes (the time between diagnosis and
the baseline examination), BMI (weight/height2 [kg/m2]),
smokingstatus(never,current),HbA1c (measuredbyion-ex-
changechromatography),FPG(measuredbyglucoseoxidase
method; Clinical Chemistry Analyzer Liasys, Italy), protein-
uria (measured by precipitation with 3% sulfosalicylic acid
and determination of turbidity by measuring absorbance
at a wavelength of 550nm with a spectrophotometer), ser-
um creatinine, triglyceride, cholesterol, HDL (measured us-
ing standardized procedures), and low-density lipoprotein
cholesterol (LDL; calculated by the Friedewald Equation
[17]) levels
Height and weight were measured using standard appa-
ratus, with the subjects in light clothes and without shoes.
Weight was measured to the nearest 0.1kg on a calibrated
beam scale. Height was measured to the nearest 0.5cm and
assessed at baseline only. A physician measured the systolic
anddiastolicBPsoftheparticipants(aftertheyhadbeenseat-
ed for 10 minutes) using a mercury sphygmomanometer and
standard techniques. All clinical and laboratory measure-
ments at baseline and followups were made using the same
standardized protocol.
2.5. Determination of MetS Incidence. I n c i d e n c eo fM e t Sw a s
expressed as the number of cases of MetS per 1,000 patient-
years of followup. As the relevant period was considered, the
dateofcompletionofthebaselineexaminationbetween1992
and 2009 until the either (i) occurrence of MetS, (ii) the date
of the last completed followup, (iii) death, or (iv) end of fol-
lowup on December 31, 2009, whichever came ﬁrst.
2.6. Statistical Analysis. The statistical methods used includ-
ed the Student’s t-test; chi-square test, analysis of variance
(ANOVA) or Kruskal-Wallis tests for normally or nonnorm-
ally distributed continuous variables, respectively and Cox’s
proportional hazards model. Univariate and multivariate
Cox’s proportional hazards models were ﬁtted to identify
predictorsofnew-onsetMetSusingSPSSversion18forWin-
dows (SPSS Inc., Chicago, IL, USA). All the signiﬁcant vari-
ables in the bivariate analysis were included as independent
variables in a multivariate Cox’s proportional hazards mod-
els. Adjustment for age was examined in separate models.
Age-adjusted means were calculated and compared using
generallinearmodels.Alltestsforstatisticalsigniﬁcancewere
two-tailed, conﬁdence intervals (CIs) were set at 95%, and
P<0.05 was considered signiﬁcant.
3. Results
3.1. Subject Characteristics. Diﬀerences in distribution of
several risk factors among 1,461 men and 1,586 women are
shown in Table 1. Women had slightly lower creatinine, were
lesslikelytobesmokers,andwereyoungeratregistrationand
had lower dyslipidemia than men. Men had lower BMI, total
cholesterol, HDL, and LDL cholesterol than women. The
mean (SD) BMI was 24.0 (3.3) kg/m2 for men and 25.7 (4.3)
kg/m2 for women. The prevalence of overweight (BMI ≥ 25)
was 25.1% (95%CI: 22.7 and 27.4%) in men, and 45.1%
(95%CI: 42.5 and 47.8%) in women. Only 8.1% (95%CI:
6.7 and 9.8%) of men, and 5.10% (95%CI: 4.0 and 6.4%)
of women were underweight (BMI ≤20). The majority of
patientswereonoralagent(61.0%),and22.6%ofthesampleISRN Endocrinology 3
Table 1: Age and age-adjusted means (SE) and proportions of
selected characteristics among 1461 men and 1586 women.
Variables Men Women
Mean (SE) Mean (SE)
Age at registration (yr.) 52.3 (0.28) 48.7 (0.27)∗∗∗
Duration of diabetes (yr.) 6.5 (0.16) 6.2 (0.15)
Age at diagnosis (yr.) 43.9 (0.16) 44.2 (0.15)
BMI (Kg/m2) 24.0 (0.11) 25.7 (0.10)∗∗∗
Systolic BP (mmHg) 116.1 (0.37) 115.1 (0.35)∗
Diastolic BP (mmHg) 72.0 (0.27) 71.8 (0.25)
Fasting blood glucose (mg/dL) 203.4 (2.11) 199.0 (2.02)
HbA1 (%) 8.8 (0.10) 8.5 (0.10)∗
Creatinine (mg/dL) 1.04 (0.03) 0.88 (0.02)∗∗∗
Triglyceride (mg/dL) 164.2 (3.21) 156.0 (3.10)
Cholesterol (mg/dL) 201.0 (1.25) 213.1 (1.20)∗∗∗
HDL Cholesterol (mg/dL) 46.9 (0.66) 55.8 (0.66)∗∗∗
LDL Cholesterol (mg/dL) 118.4 (2.32) 126.6 (2.34)∗
%%
Obesity (BMI ≥30)
Currentsmoker 32.5 2.6∗∗∗
Dyslipidemia† 37.1 32.6∗
Therapeutic regimen
Diet 21.7 23.4∗
Oral agent 61.5 60.6
Insulin 16.9 16.1
Education
Primary or below 46.7 72.2∗∗∗
Secondary 32.3 22.2
Matriculation or above 21.0 5.6
∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001. BP: blood pressure; HDL: high
density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.
†Dyslipidemia: triglyceride ≥150mg/dL (≥1.7mmol/L) or HDL cholesterol
< 40mg/dL (<0.9mmol/L) in men or <50mg/dL (<1.0mmol/L) in women.
was on diet and exercise. A total of 16.4% of patients were on
insulin treatment.
3.2. Prevalence. As deﬁned by the modiﬁed NCEP/ATP III
criteria, of the 11,281 patients with T2DM, 7,132 (2,584 men
and4,548women)hadMetS.OverallprevalenceofMetSwas
63.2% (95%CI: 62.3 and 64.1). Prevalence rates were higher
in women (68.8% (95%CI: 67.7 and 69.9) than men (55.3%
(95%CI: 53.9 and 56.8). The prevalence of MetS increased
with age. Of the 1,412 patients who were insulin-treated,
772 had MetS, giving a prevalence of 54.7% (95%CI: 52.1
and 57.3). This was lower than the prevalence rates seen for
noninsulin-treated, 66.3% (95%CI: 65.3 and 67.2).
Most of diabetic patients had three components of the
syndrome (36.4%), 23.4% had four, and 3.4% had ﬁve
components. Only 9.2% of the diabetic patients were free
fromanyothercomponentsofthesyndrome,and27.6%had
one more component.
3.3. Incidence. Of the 3,047 participants without MetS, 1017
(33.4%) (446 men and 571 women) developed MetS in
35,677 (17,205 men and 18,472 women) patient-years of fol-
lowup. The overall incidence of subsequent MetS was 28.5
(95%CI: 26.8 and 30.2) per 1,000 patient-years. Incidence
rateswerehigherinwomen(30.9(95%CI:28.4and33.4)per
1,000 patient-years) than men (25.9 (95%CI: 23.5 and 28.3).
This diﬀerence was statistically signiﬁcant (P<0.01). Of the
501 patients who were insulin-treated, 174 subsequently de-
veloped MetS, giving an incidence of 30.1 per 1,000 patient-
years (95%CI: 25.7 and 34.5). This was similar to the inci-
dence rate seen for oral agent-treated, 29.4 per 1,000 patient-
years(95%CI:27.2and31.7),butslightlyhigherthanthein-
cidence rate seen for exercise- and diet-treated 24.9 (95%CI:
21.0 and 28.2).
3.4. Risk Factors. Table 2 shows the group means (SE) and
proportions for those who did and did not develop MetS.
ThosewhodevelopedMetSweremorewomenandhadhigh-
er weight, BMI, cholesterol, number of follow-up visits, and
proportion of obesity at baseline. Those who did not de-
velope MetS were more likely to be smokers and had slightly
higher follow-up period, height, and educational level than
those who developed MetS.
A univariate analysis (Table 3) showed that age, gender,
lower HbA1c, BP, triglyceride, oral antihyperglycemic thera-
py, overweight and obesity, and no smoking were signiﬁ-
cantly associated with the risk of developing MetS. Age-ad-
justed Cox regression coeﬃcient among those free of MetS
at registration showed that signiﬁcant risk factors for devel-
oping MetS were shorter duration of diabetes, lower FPG,
cholesterol, triglyceride, creatinine, no smoking, higher ed-
ucation, oral agent or insulin treatment, and overweight and
obesity.
The incidence of MetS was also analyzed with multivari-
ate model. Cox’s proportional hazards model showed that
higher BMI (RR 1.04; 95%CI: 1.03 and 1.05), higher educa-
tion (RR 1.48; 95%CI: 1.29 and 1.69), and lower HbA1c (RR
0.90; 95%CI: 0.88 and 0.93), and treatment with insulin
(RR 1.22; 95%CI: 1.10 and 1.35) or oral agent (RR 1.25;
95%CI: 1.09, 1.43) at baseline signiﬁcantly predicted the
onset of MetS after mean 11.7 years. No other variables were
signiﬁcant.
4. Discussion
In this follow-up study of 3,047 participants, the natural
courseofMetSinpatientswithT2DMdescribed.Theincide-
nce of MetS was 28.5 per 1,000 patient-years over an average
followup of 11.7 years. The incidence rates were 25.9 per
1,000 patient-years in men and 30.9 in women. It seems
that the higher BMI, educational level, lower HbA1c,a n d
treatment with insulin or oral agent at baseline, the higher
the risk of progression to MetS. To our knowledge, little re-
search has been done to estimate incidence of MetS in pa-
tients with T2DM. Therefore, we cannot compare our ﬁnd-
ings with those of other studies. Incidence and prevalence
rates of MetS in general populations in various studies from
around the world show considerable variation [18, 19].
Estimates of incidence and prevalence of MetS will depend4 ISRN Endocrinology
Table 2: Age and age-adjusted means (SE) and proportions of selected baseline characteristics between 1017 patients with type 2 diabetes
who did and 2030 who did not develop metabolic syndrome (MetS).
Variables Developed MetS Not developed MetS Diﬀerence (95%CI)
Mean (SE) Mean (SE)
Age at registration (yr.) 50.8 (0.34) 50.2 (0.24) 0.6 (−0.23, 1.43)
Duration of diabetes (yr.) 6.2 (0.18) 6.4 (0.13) −0.2 (−0.62, 0.32)
Age at diagnosis (yr.) 44.3 (0.18) 44.0 (0.13) 0.3 (0.00, 1.59)
Followup (yr.) 11.6 (0.15) 12.0 (0.11) −0.4 (−1.13, −0.39)∗∗∗
Number of follow-up visits 15.6 (0.41) 9.6 (0.29) 6.0 (5.01, 6.99)∗∗∗
Height (cm) 159.8 (0.29) 161.5 (0.21) −1.7 (−2.41, −0.99)∗∗∗
Weight (kg) 66.8 (0.36) 64.0 (0.25) 2.8 (1.68, 3.73)∗∗∗
BMI (Kg/m2) 26.0 (0.12) 24.3 (0.09) 1.7 (1.40, 2.00)∗∗∗
Systolic BP (mmHg) 116.1 (0.43) 115.3 (0.31) 0.8 (−0.30, 1.90)
Diastolic BP (mmHg) 72.4 (0.31) 71.6 (0.23) 0.8 (0.00, 1.56)
Fasting glucose (mg/dL) 203.5 (2.49) 200.0 (1.78) 3.5 (−2.50, 9.50)
HbA1c (%) 8.7 (0.11) 8.6 (0.09) 0.1 (−0.18, 0.38)
Creatinine (mg/dL) 0.94 (0.03) 0.97 (0.02) −0.03 (−0.10, 0.04)
Triglyceride (mg/dL) 162.8 (3.77) 158.3 (2.76) 4.5 (−4.65, 13.70)
Cholesterol (mg/dL) 210.7 (1.48) 205.5 (1.07) 5.2 (−1.61, −8.79)∗∗
HDL cholesterol (mg/dL) 51.0 (0.74) 51.6 (0.68) −0.6 (−2.58, 1.38)
LDL cholesterol (mg/dL) 124.0 (2.44) 121.2 (2.24) 2.8 (−3.51, 9.51)
%%
Men 43.9 50.0 −6.1 (−9.9, −2.4)∗∗
Obesity (BMI ≥30) 15.7 8.4 7.3 (4.7, 10.00)∗∗∗
Dyslipidemia† 33.6 35.4 −1.8 (−5.4, 1.9)
Currentsmoker 12.9 19.5 −6.6 (−9.71, −3.61)∗∗∗
Therapeutic regimen
Diet 20.7 23.5 −2.8 (−5.81, 0.38)
Oral agent 62.1 60.5 1.6 (−1.97, 5.35)
Insulin 17.1 16.1 1.0 (−1.79, 3.84)
Education
Primary or below 64.2 57.6 6.6 (2.82, 10.30)∗∗
Secondary 25.4 28.0 −2.6 (−5.92, 0.89)
Matriculation or above 10.3 14.4 −4.1 (−6.54, −1.57)∗∗
∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001. CI: Conﬁdence interval; BP: blood pressure; HDL: high-density lipoprotein cholesterol; LDL: low-density
lipoprotein cholesterol. The diﬀerence in the mean or percentage of the variables between MetS and no MetS. †Dyslipidemia: triglyceride ≥150mg/dL
(≥1.7mmol/L) or HDL cholesterol < 40mg/dL (<0.9mmol/L) in men or <50mg/dL (<1.0mmol/L) in women.
upon the methodological factors, the deﬁnition of the MetS
used, and the composition of the community examined by
age, gender, ethnicity, and social class, making comparisons
betweenstudiesoflimitedvalues.Severalcross-sectionaleva-
luations conducted at diﬀerent moments and in diﬀerent po-
pulations show considerable variation. The prevalence of
MetSinpeoplewithT2DMof63.2%asreportedinthisstudy
is much higher than the values reported in general popula-
tions [9, 20–22] and similar to the studies on T2DM from
other diabetic populations [23–25].
The incidence rate of MetS that we report in the present
study is lower than that reported in low-risk population
studies carried out in the Japan [26], Europe [27], and No-
rth America [28–30] may be due to routine diabetes care.
Patients with higher BP and dyslipidemia were treated dur-
ing routine care. Baltimore Longitudinal Study of Aging
reported an incidence of 25.5% in men and 14.8% in women
a f t e ra na v e r a g ef o l l o w u po f6y e a r s[ 28]. The Insulin Resis-
tance Atherosclerosis Study reported an incidence of 17.1%
in men and 20.9% in women after a follow-up period of 5
years [29]. Longitudinal study of Japanese men ages 35 to
59 reported that incidence of MetS was 3.6 per 100 person-
years [26]. Longitudinal study of Korean male workers aging
from 30 to 39 reported that incidence of MetS was 77
per 1,000 person-years [31]. Another study from an urban
area of Portugal reported an incidence of 47/1,000 person-
years, similar in men and women [27]. But it is higher than
that reported in the San Antonio Heart Study. It showed
a 15% incidence of MetS in men and a 17% in women
after 8 years of followup [30]. The threshold values used
to deﬁne MetS criteria were higher than those indicated
by NCEP/ATP III for lipids (triglyceride ≥200mg/dL, HDLISRN Endocrinology 5
Table 3: Incidence rates and relative risks (RR) for metabolic syndrome by baseline variables.
Variables At risk Case Person-year Incidence/1000
person-year
Crude RR Age-adjusted RR
(95% CI)†
(number) (number) (95% CI)
All 3,047 1017 35677 28.5 — —
Gender
Men 1,461 446 17205 25.9 1.00 1.00
Women 1,586 571 18472 30.9 1.19 (1.06, 1.35)∗∗ 0.99 (0.84, 1.70)
Age (yr.)
<40 485 133 5552 23.9 1.00 —
40–49 946 321 10603 30.3 1.27 (1.04, 1.54)∗∗ —
50–59 946 351 10732 32.7 1.37 (1.12, 1.66)∗∗ —
60–69 508 165 6700 24.6 1.03 (0.82, 1.29) —
≥70 160 47 2134 22.0 0.92 (0.66, 1.28) —
Age at diagnosis (yr.)
<30 198 58 2333 24.9 1.00 —
30–59 2584 874 30116 29.0 1.16 (0.90, 1.52) —
≥60 251 80 3126 25.6 1.03 (0.74, 1.44) —
Duration of diabetes (yr.)
<5 1,551 522 17101 30.5 1.00 1.00
5–7 540 173 6450 26.8 0.88 (0.74, 1.04) 0.85 (0.77, 0.94)∗∗
8–11 422 143 5104 28.0 0.92 (0.77, 1.10) 0.79 (0.71, 0.88)∗∗∗
≥12 522 174 6927 25.1 0.82 (0.70, 0.98) 0.71 (0.65, 0.80)∗∗∗
Fasting glucose (mg/dL)
<100 139 51 1428 35.7 1.00 1.00
≥100 2809 951 33258 28.6 0.80 (0.61, 1.06) 0.78 (0.66, 0.93)∗∗
HbA1c (%)
<6.5 258 99 1407 70.4 1.00 1.00
≥6.5 1,034 423 8667 48.8 0.69 (0.56, 0.86)∗ 0.51 (0.45, 0.59)∗∗∗
Systolic BP (mmHg)
<130 2556 919 28892 31.8 1.00 1.00
≥130 348 96 4410 21.8 0.69 (0.56, 0.84)∗∗ 0.90 (0.80, 1.01)
Diastolic BP (mmHg)
<85 2709 966 30796 31.4 1.00 1.00
≥85 189 49 2413 20.3 0.65 (0.49, 0.86)∗∗ 0.88 (0.76, 1.02)
Cholesterol (mg/dL)
<200 1332 429 14494 29.6 1.00 1.00
200–219 512 182 6038 30.1 1.02 (0.86, 1.21) 0.84 (0.76, 0.93)
>220 1010 373 12892 28.9 0.98 (0.85, 1.12) 0.75 (0.69, 0.81)∗∗∗
HDL (mg/dL)
Men ≥40 & women ≥50 438 210 3883 54.0 1.00 1.00
Men <40 & women <50 106 39 989 39.4 0.73 (0.52, 1.02) 0.85 (0.68, 1.05)
LDL (mg/dL)
<100 144 57 1226 46.5 1.00 1.00
≥100 388 186 3533 52.6 1.13 (0.85, 1.51) 0.86 (0.71, 1.05)
Triglyceride (mg/dL)
<150 1951 693 21754 31.9 1.00 1.00
≥150 878 292 11276 25.9 0.81 (0.71, 0.93)∗∗ 0.73 (0.67, 0.79)∗∗∗
BMI (kg/m2)
<25 1688 511 20077 25.5 1.00 1.00
25–29.9 644 300 6739 44.5 1.75 (1.52, 2.01)∗∗∗ 1.24 (1.12, 1.35)∗∗∗
≥30 293 153 2803 54.6 2.14 (1.80, 2.56)∗∗∗ 1.47 (1.29, 1.67)∗∗∗6 ISRN Endocrinology
Table 3: Continued.
Variables At risk Case Person-year Incidence/1000
person-year
Crude RR Age-adjusted RR
(95% CI)† (number) (number) (95% CI)
Smoking
Nonsmoker 1979 677 25960 26.1 1.00 1.00
Currentsmoker 416 100 5820 17.2 0.66 (0.54, 0.81)∗∗∗ 0.87 (0.74, 0.98)∗
Education
Primary or below 1718 621 21273 29.2 1.00 1.00
Secondary 778 246 8142 30.2 1.03 (0.89, 1.20) 1.25 (1.14, 1.36)∗∗∗
Matriculation or above 374 100 3782 26.4 0.90 (0.74, 1.12) 1.37 (1.23, 1.54)∗∗∗
Creatinine (mg/dL)
≤1.5 2159 823 22669 36.3 1.00 1.00
>1.5 61 21 841 25.0 0.69 (0.45, 1.05) 0.60 (0.47, 0.77)∗∗∗
Therapeutic regimen
Diet 687 211 8471 24.9 1.00 1.00
Oral agent 1860 632 21480 29.4 1.18 (1.01, 1.38)∗∗∗ 1.25 (1.11, 1.40)∗∗∗
Insulin 500 174 5777 30.1 1.21 (0.99, 1.49) 1.20 (1.10, 1.32)∗∗∗
Total number of patient-years and at risk is not the same for each variable because of missing values. †Relative risks (with 95%CI) calculated by Cox’s
proportional hazards model. CI: Conﬁdence interval; RR: relative risk; BP: blood pressure; HDL: high-density lipoprotein cholesterol; LDL: low-density
lipoprotein cholesterol. ∗P<0.5, ∗∗P<0.01, and ∗∗∗P<0.001.
<35mg/dL in men and <45mg/dL in women) and BP (BP
≥140/90mmHg for systolic and diastolic, resp.). However,
our ﬁndings indicate that patients with T2DM appearing
at higher risk for developing MetS do not actually develop
it. A possible explanation is that these patients may adjust
their habits toward healthier lifestyle, besides receiving
appropriate treatment for hypertension and hyperlipidemia.
Several risk factors predicted the incidence MetS in our
study. Univariate analysis (Table 3) shows an expected pat-
tern of association for many variables with the development
of MetS. Participants who subsequently developed MetS
had greater obesity, higher triglycerides, lower smoking, and
higherproportionofinsulin-ororalagent-treatedatbaseline
than those who did not develop the MetS. In multivariate
analysis, fewer remain independently associated. The people
with T2DM who were insulin- or oral agent-treated were at
higher risk of MetS than those who treated with diet and
exercise. Insulin or oral agent treatment may indicate a more
severe disease process. A higher incidence of MetS among in-
sulin- or oral agent-treated patients could be attributable
to their longer duration of diabetes, younger age at onset,
and poorer metabolic control than in noninsulin-treated
diabetes. Other longitudinal studies documented the pivotal
role of obesity in the pathogenesis of MetS in diﬀerent popu-
lations, although the deﬁnition of MetS adopted varied from
study to study [28, 30].
The lack of correlation between incident MetS and
elevated BP at baseline in our patients is not surprising. In
fact, this sort of “dissociation” may aﬀect the decision-mak-
ing process in a clinical setting tailored for preventing MetS
and cardiovascular events.
TheroleofgenderasariskfactorforM etSremainsunset-
tled. There have been conﬂicting reports about the relation-
ship between gender and MetS incidence in general popula-
tions; in some studies MetS incidence was higher in women
[27, 30]; whereas in other studies it was higher in men [32,
33]. Similar to our results, some other cohorts from diﬀerent
ethnic background reported no signiﬁcant diﬀerences rega-
rding gender [29, 34, 35].
The higher MetS incidence found in lower values of
HbA1 was probably related to this fact that patients with
higher values of HbA1 probably are more deﬁcient in insulin
and less insulin resistant, which could have reduced their
probability to present MetS. However, this warrants further
study.
Some limitations warrant consideration. The Isfahan
clinical information system for diabetes provides one of the
largest clinic-based data sets of its kind in the developing
world. Although we have not carried out any special studies
of the validity or reliability of data for this analysis, a
clerk was employed to check consistency and, where possi-
ble, to ensure completeness of data. Previous studies show
that these patients are a representative sample of known
diabetic patients of Isfahan [36]. Our experience with other
parts of the data set gives us some conﬁdence that data qual-
ityissuﬃcientforthistypeofstudy,andthatourresultspro-
vide useful additional evidence on the incidence of and risk
factors for MetS. The study was clinic, rather than popula-
tion-based,andsomaynotcontainaclinicalspectrumrepre-
sentative of diabetic patients in the community. Many pa-
tients requiring only oral or dietary treatment may never
attend the clinic. Clinic-based estimates of the incidence or
prevalence of complications are most likely to be aﬀected by
referral patterns. Selection bias is less likely to aﬀect inci-
denceratesandassociationsbetweenriskfactorsandcompli-
cations as investigated in this study. The study was perform-
ed according to the modiﬁed NCEP/ATP III criteria [14]. We
used BMI instead of waist circumference due to unavailabil-
ity of data regarding waist circumference in our database.
The central pattern of distribution, with its higher weightingISRN Endocrinology 7
of waist circumference, is associated with more insulin resis-
tance than is the peripheral pattern of distribution [37, 38].
Nevertheless, although waist measurement is easy and not
time-consuming, waist is not routinely measured in clinical
practice. A number of studies have also shown that BMI is as
eﬀective as waist circumference for predicting the develop-
ment of T2DM and other metabolic disturbances [5, 8, 15,
16]. In addition, the Japan Society for the Study of Obesity
has reported that BMI can estimate visceral fat measured by
computed tomography as robustly as waist circumference,
and that obesity-related complications increase for a BMI of
25 [39]. An additional limitation of the present study is rep-
resented by the lack of information on the eﬀect of medica-
tions(lipidsloweringandantihypertensive)onthetrajectory
ofMetScomponents. Despitetheabovelimitations, theﬁnd-
ings here add to our understanding of the incidence, preval-
ence, risk factors, and the natural course of MetS in patients
with T2DM in Iran. Furthermore, this study provides new
datafromIran,adevelopingcountrythathasbeenunderrep-
resented in past studies.
In conclusion, this longitudinal study provides informa-
tion on the high prevalence but low incidence rate of MetS in
patientswithT2DMinIsfahan,Iran.Ourstudyshowsthatin
routine practice the natural course of MetS in patients with
T2DM is dynamic. The clinical management of patients with
T2DM will contribute signiﬁcantly to MetS prevention.
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